Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the period of April 2026, specifically dated April 8, 2026. The report details new clinical data from the ongoing Phase 2 COACH Trial, which evaluates a combination therapy of once-weekly TransCon CNP and once-weekly TransCon hGH for children with achondroplasia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or operational financial data.
Material Changes and Clinical Results
The primary material update is the announcement of Week 52 data from the COACH Trial, demonstrating benefits beyond linear growth:
- Arm Span Improvements: Mean change in achondroplasia-specific arm span Z-scores was +1.02 for TransCon CNP treatment-naïve children and +0.66 for previously treated children. Absolute improvements were +9.4 cm and +7.9 cm, respectively, compared to approximately 8 cm per arm via limb lengthening surgery.
- Spinal Canal Dimensions: Mean changes in L1-L5 interpedicular distance (IPD) were +1.7 mm (naïve) and +1.1 mm (treated), compared to +0.6 mm for monotherapy in the ApproaCH trial. These improvements may reduce nerve compression and pain.
- Lower Limb Alignment: For the naïve cohort, the mean change in tibial femoral angle (TFA) Z-score was -0.86 (combination) versus -0.47 (monotherapy). In absolute terms, the mean change in TFA was -3.0 degrees (combination) versus -1.3 degrees (monotherapy).
- Safety and Tolerability: All children completed 52 weeks of treatment with no acceleration of bone age and maintained safety profiles consistent with prior reports.
Guidance, Outlook, and Risks
Management commentary highlights the potential of the combination therapy as a differentiated treatment for short stature in growth hormone-sufficient settings. The filing includes standard forward-looking statements regarding future operations and regulatory approvals.
Key risks and contingencies identified include:
- Dependence on third-party manufacturers and distributors.
- Regulatory review risks, including potential delays or labeling restrictions in the US, EU, and other jurisdictions.
- Clinical development risks where future trials may not confirm earlier data.
- Manufacturing, supply chain, and quality issues.
- Market acceptance, pricing, and reimbursement challenges.
- Intellectual property litigation and freedom-to-operate risks.
- Geopolitical and economic factors, including currency fluctuations and trade policies.
Investor Verification Checklist
- Verify the full safety profile and long-term tolerability data beyond Week 52 for the combination therapy.
- Confirm the regulatory pathway and timeline for potential approval of the combination therapy in key markets.
- Assess the commercial viability and reimbursement landscape for a combination therapy versus monotherapy.
- Review the company's cash position and funding requirements in the most recent Form 20-F, as this filing contains no financial data.
- Monitor upcoming data releases regarding the durability of arm span and spinal canal improvements.